Table 1.

Clinical characteristics of study participants at baseline and 1 year^*

Characteristic	Control (n = 6)	PAH Baseline (n = 14)	PAH at 1 yr (n = 12)
PAH subgroup (idiopathic/hereditary/associated)	—	9/3/2	8/2/1
WHO functional class (I/II/III/IV)	—	1/12/1/0	1/10/0/1
Age, yr	44 ± 3	46 ± 3	45 ± 3
Race, caucasian/African American	6/0	13/1	11/1
Sex, M/F	0/6	3/11	3/9
Heart rate, beats/min	65 ± 6	74 ± 3	75 ± 4
BMI, kg/m2	30 ± 4	27 ± 1	27 ± 1
MAP, mm Hg	91 ± 6	77 ± 3	80 ± 2
6-min-walk distance, ft	—	1,580 ± 92	1,579 ± 96
SpO2 during walk, %†	—	93 ± 1	94 ± 1
BNP, pg/ml‡	—	124 ± 56	122 ± 41

Definition of abbreviations: BMI = body mass index; BNP = B-type natriuretic peptide; MAP = mean arterial pressure; PAH = pulmonary arterial hypertension; WHO = World Health Organization.

^*Data presented as mean ± SEM or as n. Paired t tests revealed no significant changes over 1 yr (P > 0.3, except age, where P < 0.0001). There were no significant differences between control and participants with PAH,at baseline (P > 0.05).

^†On room air except one patient on a 2-liter nasal cannula at baseline.

^‡Only available for 12 patients at baseline and 10 patients at follow-up.